SG Americas Securities LLC Buys 1,765 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

SG Americas Securities LLC lifted its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 231.6% in the third quarter, Holdings Channel.com reports. The fund owned 2,527 shares of the company’s stock after purchasing an additional 1,765 shares during the period. SG Americas Securities LLC’s holdings in Krystal Biotech were worth $460,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently made changes to their positions in the stock. Jamison Private Wealth Management Inc. bought a new stake in Krystal Biotech during the second quarter valued at $28,000. GAMMA Investing LLC boosted its stake in Krystal Biotech by 160.3% during the second quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock valued at $28,000 after buying an additional 93 shares during the period. Key Financial Inc bought a new stake in Krystal Biotech during the second quarter valued at $28,000. Blue Trust Inc. boosted its stake in Krystal Biotech by 2,328.6% during the second quarter. Blue Trust Inc. now owns 170 shares of the company’s stock valued at $30,000 after buying an additional 163 shares during the period. Finally, Quest Partners LLC bought a new stake in Krystal Biotech during the second quarter valued at $71,000. 86.29% of the stock is owned by institutional investors.

Krystal Biotech Trading Down 0.4 %

KRYS opened at $177.78 on Thursday. The company has a market cap of $5.08 billion, a P/E ratio of 95.07 and a beta of 0.82. The business’s 50-day moving average price is $186.81 and its 200-day moving average price is $180.05. Krystal Biotech, Inc. has a 12 month low of $93.95 and a 12 month high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, August 5th. The company reported $0.53 EPS for the quarter, topping the consensus estimate of $0.50 by $0.03. The firm had revenue of $70.28 million for the quarter, compared to the consensus estimate of $65.27 million. Krystal Biotech had a return on equity of 1.99% and a net margin of 63.73%. The company’s quarterly revenue was up 70283900.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.25) earnings per share. Equities research analysts forecast that Krystal Biotech, Inc. will post 3.13 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

KRYS has been the subject of several research analyst reports. Evercore ISI lifted their price objective on Krystal Biotech from $201.00 to $206.00 and gave the company an “outperform” rating in a research note on Monday, August 12th. HC Wainwright raised their price target on Krystal Biotech from $200.00 to $221.00 and gave the company a “buy” rating in a research report on Wednesday, August 28th. Stifel Nicolaus raised their price target on Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. Cantor Fitzgerald restated an “overweight” rating on shares of Krystal Biotech in a research report on Thursday, August 29th. Finally, Chardan Capital raised their price target on Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a research report on Monday, August 5th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Krystal Biotech has an average rating of “Buy” and a consensus target price of $196.75.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $197.76, for a total value of $4,944,000.00. Following the transaction, the insider now owns 1,500,882 shares in the company, valued at approximately $296,814,424.32. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 14.10% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).